Participating Companies
Google translate:
“UQM Department of Chemistry and Biochemistry
University of Quebec in Montreal
JOB OFFER: Research Assistant / Associate
Job type: Full time
Start: Immediately
Duration: 1 year (renewable)
Place of work: Molecular Oncology Laboratory (Chemistry Department, UQAM)
Background: Our molecular oncology research laboratory is interested in the development and
the characterization of a new therapeutic approach against cancer. this project is being carried out in collaboration with Theratechnologies Inc., a biopharmaceutical company specializing in the marketing and development of drugs that meet unmet needs and is jointly funded by the Consortium Qubcois pour la Dcouverte du Mdicament (CQDM) and the Canadian Cancer Society .
Job Description: The Research Assistant/Associate will work under the supervision of the Principal Investigator or a Senior Research Associate. The candidate will perform various scientific and administrative tasks.
Responsibilities:
- Have excellent skills in cell culture, microscopy, immunofluorescence, cellular and molecular biology (RNA and protein extraction, RT-PCR, qPCR, Western-type immunoblotting), cytotoxicity and cell proliferation assays, and flow cytometry flux; manipulation of radioisotopes;
- Have a proven experience in pharmacology and in the development of ligand binding and internalization assays;
- Compile, analyze and interpret its results;
- Maintain an up-to-date laboratory notebook and follow standard operating procedures;
- Participate in tasks necessary for the proper functioning of the laboratory.
Required requirements:
- A university degree (M.Sc., Ph.D.) in biomedical sciences, cell biology, biology,
biochemistry. onarmaco osie or in a related comaine
- Experience in a pharmaceutical environment would be an asset;
- Ability to organize and document (literature review)
- Knowledge of Word, Excel, Power Point, and Graph Pad Prism software.
Personal qualities :
- Positive, enthusiastic, and highly motivated personality;
- Autonomy, sense of responsibility;
- Ability to set goals and meet deadlines;
- Ability to work under pressure and set priorities;
UQM Department of Chemistry and Biochemistry
University of Quebec in Montreal
- Ability to generate ideas and find solutions;
- Ability to work both alone and in a team;
- Esorit of guinea and propensity to help each other:
- Flexibility and flexibility.
Conditions of employment: Contracted salary according to the candidate's experience and qualifications based on the salary scales in effect at UQAM.
Submission of applications: Interested candidates should send their CV, a brief cover letter, and the contact details of 2-3 references by email to Borane Annabi
[annabi.borhane@ugam.ca)
Principal Investigator:
Borhane Annabi, Ph.D.
Associate Professor
Chair in Cancer Prevention and Treatment
University of Quebec in Montreal, Department of Chemistry Montreal, Quebec, Canada
P.S. We thank all applicants for their interest. Only the people selected for an interview will be contacted. UQAM subscribes to employment equity.”
https://www.linkedin.com/posts/cyndia-charfi-1b27223a_offre-demploi-activity-6994831055824248832-zmo4?utm_source=share&utm_medium=member_ios
It looks like THTX is attending this conference in January as a participant taking to investors. Also UQAM put a job posting looking for a research assistant last month.
On first one if the prospects of the company’s all operations including R&D were as bad as the market thinks it is why even bother to present it to investors?
On the second one UQAM seems to be exploring the potentials of Sort1 technology!
On a different note CYDY’s valuation depreciated almost 50 per cent after announcement of the changes against the former CEO three days later they announced a conference call will be held on December 29 to discuss the performance of their drug in the clinical trials and the charges against the former CEO. The stock regained some 50 percent of the losses.
THTX’s investor presentation has been down for weeks and nothing on their social media platforms for days the result stock is down some 50 or more per cent and stayed down!
As some one elsewhere mentioned the ambulance chaser are doing better job reaching out to shareholders than the company which in my opinion should be the other way around when panic selling resulted in such depreciation from levels that many believed were already extremely low. They put a post earlier about their vibrant team and overall success to calm down their employees but some 4 weeks later the shareholders are still waiting for some clarification it doesn’t need to be detailed or finalized but release enough information so the shareholders get an idea what is the plan, get the sense that this company can handle negative eventualities and care about their shareholders. There have been so many speculation from the current oncology program is dead to many suggestions about alternatives. We need to hear from the capable team directly and it should have happened already. I sent an email to the IR last week with some simple questions no surprise nothing back. Their communication/interaction in critical moments goes from bare minimum to nothing so frustrated shareholders go as far as contacting crooked lawyers which brings more disruptions/damage to their reputation. THTX, you have read here, elsewhere what the investors complain about address it in timely manner to the best you can. At times we wondered whether NASH is still on the table due to long periods of radio silence don’t make the same mistake with Sort1 platform.